194
Views
3
CrossRef citations to date
0
Altmetric
Letters to the Editor

A novel e8a2 BCR–ABL1 fusion with insertion of RALGPS1 exon 8 in a patient with relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia

, , , , , , & show all
Pages 919-921 | Received 02 Nov 2010, Accepted 07 Jan 2011, Published online: 21 Feb 2011

References

  • Gruber F, Mustjoki S, Porkka K. Impact of tyrosine kinase inhibitors on patient outcomes in Philadelphia chromosome-positive acute lymphoblastic leukaemia. Br J Haematol 2009; 145:581–587.
  • Burmeister T, Schwartz S, Taubald A, et al. Atypical BCR-ABL mRNA transcripts in adult acute lymphoblastic leukaemia. Haematologica 2007;92:1699–1702.
  • Demehri S, Paschka P, Schultheis B, et al. e8a2 BCR-ABL: more frequent than other atypical BCR-ABL variants? Leukemia 2005;19:681–684.
  • Cayuela JM, Rousselot P, Nicolini F, et al. Identification of a rare e8a2 BCR-ABL fusion gene in three novel chronic myeloid leukemia patients treated with imatinib. Leukemia 2005;19:2234–2236.
  • Tchirkov A, Couderc J-L, Perissel B, et al. Major molecular response to imatinib in a patient with chronic myeloid leukemia expressing a novel form of e8a2 BCR-ABL transcript. Leukemia 2006;20:167–168.
  • Martinelli G, Terragna C, Amabile M, et al. Translisin recognition site sequences flank translocation breakpoints in a Philadelphia chromosome positive chronic myeloid leukemia patient expressing a novel type of chimeric BCR-ABL transcript (E8-INT-A2). Leukemia 1999;13:1635–1637.
  • How GF, Lim LV, Kulkarni S, Tan LT, Tan P, Cross NCP. Two patients with novel BCR/ABL fusion transcripts (e8/a2 and e13/a2) resulting from translocation breakpoints within BCR exons. Br J Haematol 1999;105:434–436.
  • Rowe JM, Buck G, Burnett AK, et al. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. Blood 2005;106:3760–3767.
  • van Dongen JJ, Macintyre EA, Gabert JA, et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the Biomed-1 concerted action: investigation of minimal residual disease in acute leukemia. Leukemia 1999;13:1901–1928.
  • Demehri S, O'Hare T, Eide CA, et al. The function of the pleckstrin homology domain in BCR-ABL mediated leukemogenesis. Leukemia 2010;24:226–229.
  • Rebhun JF, Chen H, Quillam LA. Identification and characterization of a new family of guanine nucleotide exchange factors for the Ras-related GTPase Ral. J Biol Chem 2000;275:13406–13410.
  • de Bruyn KMT, de Rooj J, Wolthuis RMF, et al. Ral GEF2, a pleckstrin homology domain containing guanine nucleotide exchange factor for Ral. J Biol Chem 2000;275:29761–29766.
  • Bodemann BO, White MA. Ral GTPases and cancer: linchpin support of the tumorigenic platform. Nat Rev Cancer 2008;8: 133–140.
  • Specchia G, Albano F, Anelli L, et al. Deletion on der(9) chromosome in adult Ph-positive acute lymphoblastic leukemia occur with a frequency similar to that observed in chronic myeloid leukemia. Leukemia 2003;17:528–531.
  • Castagnetti F, Testoni N, Luatti S, et al. Deletions of the derivative chromosome 9 do not influence the response and the outcome of chronic myeloid leukemia in early chronic phase treated with imatinib mesylate: GIMEMA CML Working Party analysis. J Clin Oncol 2010;28:2748–2754.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.